Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.

NCT07742956 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: ALK201 for injection
DRUG: Ivonescimab Injection

Sponsor

Shanghai Allink Biotherapeutics Co., Ltd.